Shareholder Vote Scheduled for Ligand Pharmaceuticals Acquisition at $39.00 Cash Plus Contingent Value Right
Summary
XOMA Royalty Corp. filed its definitive proxy statement for a special meeting on July 13, 2026, seeking shareholder approval for its acquisition by Ligand Pharmaceuticals for $39.00 cash per share plus a contingent value right (CVR).
Key Events
-
Shareholder Vote Scheduled
XOMA Royalty Corp. has scheduled a special meeting for July 13, 2026, for stockholders to vote on the proposed acquisition by Ligand Pharmaceuticals.
-
Merger Consideration Details
Shareholders will receive $39.00 per share in cash and one Contingent Value Right (CVR) per share.
-
CVR Contingency
The CVRs represent a contractual right to contingent cash payments from the Janssen Litigation, which are highly uncertain, non-transferable, and may ultimately have no value.
-
Strong Shareholder Support
The Board of Directors unanimously recommends the merger, and major shareholder Biotechnology Value Fund (BVF) along with officers and directors, collectively holding 44.3% of voting shares, have signed agreements to vote in favor.
Analysis
This definitive proxy statement provides shareholders with the final details and voting instructions for the proposed acquisition of XOMA Royalty by Ligand Pharmaceuticals. The merger offers shareholders $39.00 per share in cash plus one Contingent Value Right (CVR) per share. The CVRs are tied to the outcome of the Janssen Litigation and are explicitly noted as highly contingent, non-transferable, and potentially valueless. The company's financial advisor, Leerink Partners, opined on the fairness of the $39.00 cash component but did not value the CVRs. The current stock price of $41.76 is above the $39.00 cash offer, suggesting the market is pricing in additional value from the CVRs or other factors. With the Board's unanimous recommendation and significant shareholder support (44.3% of voting shares committed to vote in favor), the merger's approval at the July 13, 2026 special meeting is highly probable, moving the company closer to closing this significant transaction.
At the time of this filing, XOMA was trading at $41.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $733M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.